Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1962 1
1964 2
1965 1
1966 1
1969 3
1971 3
1972 4
1973 5
1974 7
1975 10
1976 13
1977 22
1978 17
1979 18
1980 14
1981 11
1982 8
1983 11
1984 9
1985 10
1986 7
1987 12
1988 12
1989 10
1990 14
1991 11
1992 9
1993 17
1994 21
1995 15
1996 25
1997 20
1998 13
1999 22
2000 18
2001 20
2002 19
2003 28
2004 32
2005 25
2006 30
2007 22
2008 25
2009 31
2010 22
2011 18
2012 30
2013 34
2014 37
2015 42
2016 28
2017 31
2018 33
2019 23
2020 24
2021 20
2022 23
2023 15
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

944 results

Results by year

Filters applied: . Clear all
Page 1
Phenprocoumon.
[No authors listed] [No authors listed] 2020 Nov 16. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2020 Nov 16. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000588 Free Books & Documents. Review.
Phenprocoumon is not approved for sale by the U.S. Food and Drug Administration (FDA). Limited information indicates that anticoagulant maternal doses of phenprocoumon produce low levels in milk. Until more data are available, shorter-acting anticoagulants are prefe …
Phenprocoumon is not approved for sale by the U.S. Food and Drug Administration (FDA). Limited information indicates that anticoagula …
Phenprocoumon poisonings.
Riesselmann B, Hollmann T, Tsokos M. Riesselmann B, et al. Leg Med (Tokyo). 2009 Apr;11 Suppl 1:S503-5. doi: 10.1016/j.legalmed.2009.03.011. Epub 2009 May 5. Leg Med (Tokyo). 2009. PMID: 19409836
Phenprocoumon is a derivative of coumarin, used as a preventative anticoagulant and in the treatment of thromboembolisms. ...A blood sample taken the following day yielded evidence of a phenprocoumon concentration of 3.1 mg/l. According to his general practitioner, …
Phenprocoumon is a derivative of coumarin, used as a preventative anticoagulant and in the treatment of thromboembolisms. ...A blood …
Warfarin pharmacogenomics: current best evidence.
Kimmel SE. Kimmel SE. J Thromb Haemost. 2015 Jun;13 Suppl 1:S266-71. doi: 10.1111/jth.12978. J Thromb Haemost. 2015. PMID: 26149035 Free article. Review.
Two larger trials of warfarin and one of the acenocoumarol and phenprocoumon have recently been published. The COAG trial addressed the incremental benefit of adding genetic information to clinical information and demonstrated no benefit from the pharmacogenetic-based dosi …
Two larger trials of warfarin and one of the acenocoumarol and phenprocoumon have recently been published. The COAG trial addressed t …
Pharmacogenomics of Oral Antithrombotic Drugs.
Storelli F, Daali Y, Desmeules J, Reny JL, Fontana P. Storelli F, et al. Curr Pharm Des. 2016;22(13):1933-49. doi: 10.2174/1381612822666151208122845. Curr Pharm Des. 2016. PMID: 26642774 Review.
This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well-studied compounds such as vitamin K antagonists (e.g., warfarin, acenocoumarol, and phenprocoumon), aspirin, and clopidogrel, as well …
This article provides a comprehensive review of the published literature about the pharmacogenomics of antithrombotic drugs, including well- …
Old and new anticoagulants.
Harbrecht U. Harbrecht U. Hamostaseologie. 2011 Feb;31(1):21-7. doi: 10.5482/ha-1149. Hamostaseologie. 2011. PMID: 21311820 Review.
Half lifes of the new anticoagulants are much shorter than that of the mainly used coumarins (phenprocoumon, warfarin), making "anticoagulation bridging" unnecessary before surgery. ...
Half lifes of the new anticoagulants are much shorter than that of the mainly used coumarins (phenprocoumon, warfarin), making "antic …
Ginger-associated overanticoagulation by phenprocoumon.
Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Krüth P, et al. Ann Pharmacother. 2004 Feb;38(2):257-60. doi: 10.1345/aph.1D225. Epub 2003 Dec 19. Ann Pharmacother. 2004. PMID: 14742762 Review.
OBJECTIVE: To report a case of ginger-phenprocoumon interaction resulting in an elevated international normalized ratio (INR) and epistaxis. CASE SUMMARY: A 76-year-old white European woman on long-term phenprocoumon therapy with an INR within the therapeutic range …
OBJECTIVE: To report a case of ginger-phenprocoumon interaction resulting in an elevated international normalized ratio (INR) and epi …
[Perioperative management of anticoagulation].
Eisele R, Melzer N, Bramlage P. Eisele R, et al. Chirurg. 2014 Jun;85(6):513-9. doi: 10.1007/s00104-014-2738-6. Chirurg. 2014. PMID: 24823997 Review. German.
In contrast, for larger interventions with a moderate to high risk of bleeding, a discontinuation of phenprocoumon with temporary bridging is required. In this case it is common practice to discontinue phenprocoumon 7-9 days preoperatively and administer heparin mos …
In contrast, for larger interventions with a moderate to high risk of bleeding, a discontinuation of phenprocoumon with temporary bri …
Non-vitamin-K oral anticoagulants (NOACs) for the prevention of secondary stroke.
Diener HC, Ntaios G, O'Donnell M, Easton JD. Diener HC, et al. Expert Opin Pharmacother. 2018 Oct;19(14):1597-1602. doi: 10.1080/14656566.2018.1515913. Epub 2018 Sep 17. Expert Opin Pharmacother. 2018. PMID: 30152249 Review.
In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effective both for primary and secondary stroke prevention with a 60-70% relative reduction in stroke risk compared with placebo. ...
In patients with atrial fibrillation (AF), oral anticoagulation with vitamin K antagonists (VKA) (warfarin, phenprocoumon) is effecti …
Pharmacogenetic differences between warfarin, acenocoumarol and phenprocoumon.
Beinema M, Brouwers JR, Schalekamp T, Wilffert B. Beinema M, et al. Thromb Haemost. 2008 Dec;100(6):1052-7. Thromb Haemost. 2008. PMID: 19132230 Review.
The effects of CYP2C9 polymorphisms on the pharmacokinetics and anticoagulant response are least pronounced in the case of phenprocoumon. In the long term, patients using phenprocoumon have more often international normalised ratio (INR) values in the therapeutic ra …
The effects of CYP2C9 polymorphisms on the pharmacokinetics and anticoagulant response are least pronounced in the case of phenprocoumon …
Carbamazepine-phenprocoumon interaction.
Böttcher T, Buchmann J, Zettl UK, Benecke R. Böttcher T, et al. Eur Neurol. 1997;38(2):132-3. doi: 10.1159/000113178. Eur Neurol. 1997. PMID: 9286639 No abstract available.
944 results